The identification of the “alternative” mechanism(s) of action specific to SGLT2 inhibitors that end(s) up by protecting and preserving the renal function in the different (and, apparently, totally unrelated) kidney diseases described above could have a major impact from a clinical point of view. Here, SLC5A2 is linked to kidney disorder.